Sensitivity of adult T‐cell leukaemia lymphoma cells to tumour necrosis factor‐related apoptosis‐inducing ligand

Tumour necrosis factor (TNF)‐related apoptosis‐inducing ligand (TRAIL) induces apoptosis in many transformed cells, but not in normal cells, and hence TRAIL has recently emerged as a novel anti‐cancer agent. Adult T‐cell leukaemia lymphoma (ATLL) is a neoplasm of T‐lymphocyte origin aetiologically associated with human T‐lymphotropic virus type 1 (HTLV‐I), and is resistant to standard anti‐cancer therapy. We thus characterized the sensitivity of ATLL cells to TRAIL in this study. Although most primary ATLL cells and cell lines expressed TRAIL death receptors on their surface, they showed only restricted sensitivity to TRAIL. Among the 10 ATLL cell lines examined, one was sensitive, but two had insufficient death‐receptor expression, two had an unknown resistant mechanism with abrogation of the death signal upstream of caspase‐8, and the remaining five showed attenuation of the signal in both extrinsic and intrinsic pathways by X‐linked inhibitor of apoptosis and Bcl‐2/Bcl‐xL respectively. Furthermore, the level of HTLV‐I tax expression was significantly correlated to TRAIL resistance. Interestingly, ATLL cells themselves expressed TRAIL on the cell surface. Constitutive production of TRAIL may offer resistance, thus allowing the development of TRAIL‐resistant ATLL cells. Consequently, the resistant mechanism in ATLL cells against TRAIL was assigned to multiple factors and was not explained by a definitive single agent.

[1]  S. Shankar,et al.  Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[2]  A. Ballestrero,et al.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Anticancer Drugs to Overcome Chemoresistance in Antiapoptotic Bcl-2 Family Members Expressing Jurkat Cells , 2004, Clinical Cancer Research.

[3]  G. Cheng,et al.  Human T-cell Leukemia Virus Type I Tax Protein Induces the Expression of Anti-Apoptotic Gene Bcl-xL in Human T-Cells through Nuclear Factor-κB and c-AMP Responsive Element Binding Protein Pathways , 2001, Virus Genes.

[4]  Jian Kang,et al.  Chemical sensitization and regulation of TRAIL‐induced apoptosis in a panel of B‐lymphocytic leukaemia cell lines , 2003, British journal of haematology.

[5]  S. Gibson,et al.  Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia , 2003, Oncogene.

[6]  G. Packham,et al.  Regulation of tumour necrosis factor‐related apoptosis‐inducing ligand (TRAIL)‐induced apoptosis in Burkitt's lymphoma cell lines , 2003, British journal of haematology.

[7]  I. Jeremias,et al.  TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB , 2003, Oncogene.

[8]  L. Foroni,et al.  Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor‐related apoptosis‐inducing ligand , 2003, British journal of haematology.

[9]  Hiroki Sato,et al.  TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. , 2003, Blood.

[10]  M. Tomonaga,et al.  The Current Status of Therapy for Adult T-cell Leukaemia-Lymphoma in Japan , 2003, Leukemia & lymphoma.

[11]  M. V. D. van den Brink,et al.  Nature's TRAIL--on a path to cancer immunotherapy. , 2003, Immunity.

[12]  G. Cohen,et al.  Death receptors leave a caspase footprint that Smacs of XIAP , 2003, Cell Death and Differentiation.

[13]  G. Cohen,et al.  Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia , 2002, Oncogene.

[14]  S. Cory,et al.  The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.

[15]  M. Tomonaga,et al.  Possible Attenuation of Fas-Mediated Signaling by Dominant Expression of Caspase-8 Aberrant Isoform in Adult T-cell Leukemia Cells , 2002, International journal of hematology.

[16]  A. Ashkenazi,et al.  Targeting death and decoy receptors of the tumour-necrosis factor superfamily , 2002, Nature Reviews Cancer.

[17]  Kenshi Hayashi,et al.  Characterization of caspase-8L: a novel isoform of caspase-8 that behaves as an inhibitor of the caspase cascade. , 2002, Blood.

[18]  P. Krammer,et al.  Tumor Immunology , 2018, Medical Immunology.

[19]  Michael Karin,et al.  NF-κB at the crossroads of life and death , 2002, Nature Immunology.

[20]  Michael Karin,et al.  NF-kappaB at the crossroads of life and death. , 2002, Nature immunology.

[21]  P. Krammer,et al.  FLICE-Inhibitory Proteins: Regulators of Death Receptor-Mediated Apoptosis , 2001, Molecular and Cellular Biology.

[22]  A. Österborg,et al.  Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D , 2001, Leukemia.

[23]  G. Xiao,et al.  NF-κB Signaling Pathway Governs TRAIL Gene Expression and Human T-cell Leukemia Virus-I Tax-induced T-cell Death* , 2001, The Journal of Biological Chemistry.

[24]  A. Spencer,et al.  TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy , 2001, Leukemia.

[25]  P. Richardson,et al.  TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. , 2001, Blood.

[26]  H. S. Kim,et al.  Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. , 2001, Cancer research.

[27]  M. Shin,et al.  Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma , 2001, Oncogene.

[28]  Yasuaki Yamada,et al.  Soluble Fas (APO-1/CD95) Isoform in Adult T-Cell Leukemia , 2001, Leukemia & lymphoma.

[29]  M. Yoshida,et al.  Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. , 2001, Annual review of immunology.

[30]  B. Dörken,et al.  In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κB activity , 2001, Leukemia.

[31]  K. Bhalla,et al.  Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. , 2000, Blood.

[32]  U. Jaeger,et al.  Expression of tumour necrosis factor (TNF)‐related apoptosis‐inducing ligand (TRAIL) receptors and sensitivity to TRAIL‐induced apoptosis in primary B‐cell acute lymphoblastic leukaemia cells , 2000, British journal of haematology.

[33]  J. Tschopp,et al.  TRAIL receptor-2 signals apoptosis through FADD and caspase-8 , 2000, Nature Cell Biology.

[34]  A. Hida,et al.  Inhibition of Caspase Cascade by HTLV-I Tax Through Induction of NF-κB Nuclear Translocation , 1999 .

[35]  M. Kannagi,et al.  Induction of Bcl-xL Expression by Human T-Cell Leukemia Virus Type 1 Tax through NF-κB in Apoptosis-Resistant T-Cell Transfectants with Tax , 1999, Journal of Virology.

[36]  S. Zhao,et al.  Functional expression of TRAIL by lymphoid and myeloid tumour cells , 1999, British journal of haematology.

[37]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[38]  V. Dixit,et al.  Apoptosis control by death and decoy receptors. , 1999, Current opinion in cell biology.

[39]  M. Tomonaga,et al.  Fas Gene Mutation in the Progression of Adult T Cell Leukemia , 1999, The Journal of experimental medicine.

[40]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[41]  A. Hida,et al.  Inhibition of caspase cascade by HTLV-I tax through induction of NF-kappaB nuclear translocation. , 1999, Blood.

[42]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[43]  Xiaodong Wang,et al.  Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.

[44]  M. Tomonaga,et al.  Interleukin-15 (IL-15) can replace the IL-2 signal in IL-2-dependent adult T-cell leukemia (ATL) cell lines: expression of IL-15 receptor alpha on ATL cells. , 1998, Blood.

[45]  J C Reed,et al.  IAPs block apoptotic events induced by caspase‐8 and cytochrome c by direct inhibition of distinct caspases , 1998, The EMBO journal.

[46]  M. Tomonaga,et al.  Interleukin-15 (IL-15) Can Replace the IL-2 Signal in IL-2–Dependent Adult T-Cell Leukemia (ATL) Cell Lines: Expression of IL-15 Receptor α on ATL Cells , 1998 .

[47]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[48]  M. Tomonaga,et al.  Features of the cytokines secreted by adult T cell leukemia (ATL) cells. , 1996, Leukemia & lymphoma.

[49]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[50]  Y. Ohtsuki,et al.  Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells , 1981, Nature.

[51]  K. Miyamoto,et al.  A novel T-cell line derived from adult T-cell leukemia. , 1980, Gan.

[52]  E. Jaffe,et al.  Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. , 1980, Blood.